A study revealed that hormonal stimulation accounted for a significant proportion of the per-cycle expenses. 8 Ovulation induction protocols mainly include gonadotropin-releasing hormone agonist (GnRH ...

All women who underwent ovarian stimulation with the GnRH antagonist or flexible PPOS (fPPOS) and received a GnRH agonist trigger were eligible for inclusion. Outcomes included number of metaphase-II ...

While oral GnRH antagonists are targeted at pain associated with endometriosis, experts also see a place for them within the therapeutic paradigm of infertility-associated endometriosis. Ongoing ...

Abstract Objectives: To evaluate the efficacy of alteration from gonadotropin-releasing hormone (GnRH) agonist to antagonist in patients with castration-resistant prostate cancer (CRPC). Methods: ...

Background and Aims: Endometriosis is known to have detrimental effects on fertility, but there is no consensus on the optimal stimulation protocol for IVF-ET in patients with endometriosis. The study ...

Results: A total of 69 and 192 cases were, respectively, included in the GnRH antagonist or GnRH agonist group. The stimulation duration was significantly longer by the GnRH agonist protocol than the ...

EP: 9. Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer EP: 10. ADT Treatment Considerations and Unmet Needs in Prostate Cancer Video content above is prompted by ...

In 2020, the phase 3 HERO trial of relugolix (oral GnRH antagonist) versus leuprolide (GnRH agonist) was published in The New England Journal of Medicine. This was a multinational, phase III, ...